115 related articles for article (PubMed ID: 38015541)
1. Mutation analysis of the TERT gene in ovarian cancer patients of the Turkish population by next generation sequencing method.
Capar Gorali B; Gulec Yılmaz S; Akdeniz FT; Attar R; İsbir T
Cell Mol Biol (Noisy-le-grand); 2023 Nov; 69(11):51-55. PubMed ID: 38015541
[TBL] [Abstract][Full Text] [Related]
2. Determination of
Yaltirik CK; Yilmaz SG; Ozdogan S; Bilgin EY; Barut Z; Ture U; Isbir T
In Vivo; 2022; 36(4):1694-1702. PubMed ID: 35738587
[TBL] [Abstract][Full Text] [Related]
3. Genomic Profiling Identifies Association of
Zhu GG; Nafa K; Agaram N; Zehir A; Benayed R; Sadowska J; Borsu L; Kelly C; Tap WD; Fabbri N; Athanasian E; Boland PJ; Healey JH; Berger MF; Ladanyi M; Hameed M
Clin Cancer Res; 2020 Jan; 26(2):419-427. PubMed ID: 31615936
[TBL] [Abstract][Full Text] [Related]
4. Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
Ferreira MSV; Sørensen MD; Pusch S; Beier D; Bouillon AS; Kristensen BW; Brümmendorf TH; Beier CP; Beier F
J Neurooncol; 2020 Mar; 147(1):1-14. PubMed ID: 31960234
[TBL] [Abstract][Full Text] [Related]
5. A novel truncated form of
Agostini A; Panagopoulos I; Davidson B; Trope CG; Heim S; Micci F
Oncol Lett; 2016 Aug; 12(2):1559-1563. PubMed ID: 27446471
[TBL] [Abstract][Full Text] [Related]
6. Primary Astrocytic Tumours and Paired Recurrences have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss.
Li X; Wei J; Liu Y; Li P; Fan L; Wang Y; Li M; Zhao D; Yu Z; Ye J; Guo Y; Yan Q; Guo S; Wang Z
Sci Rep; 2017 Oct; 7(1):13038. PubMed ID: 29026176
[TBL] [Abstract][Full Text] [Related]
7. Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas.
Wang LM; Li Z; Piao YS; Cai YN; Zhang LY; Ge HJ; Xu WW; Lu DH
Chin Med J (Engl); 2019 Dec; 132(24):2920-2926. PubMed ID: 31833906
[TBL] [Abstract][Full Text] [Related]
8. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
[TBL] [Abstract][Full Text] [Related]
9. Detection of TERT Promoter Mutations Using Targeted Next-Generation Sequencing: Overcoming GC Bias through Trial and Error.
Lee H; Lee B; Kim DG; Cho YA; Kim JS; Suh YL
Cancer Res Treat; 2022 Jan; 54(1):75-83. PubMed ID: 33940787
[TBL] [Abstract][Full Text] [Related]
10. Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients.
Schwaederle M; Krishnamurthy N; Daniels GA; Piccioni DE; Kesari S; Fanta PT; Schwab RB; Patel SP; Parker BA; Kurzrock R
Cancer; 2018 Mar; 124(6):1288-1296. PubMed ID: 29211306
[TBL] [Abstract][Full Text] [Related]
11. Telomerase reverse transcriptase promoter mutation- and O
Gramatzki D; Felsberg J; Hentschel B; Wolter M; Schackert G; Westphal M; Regli L; Thon N; Tatagiba M; Wick W; Schlegel U; Krex D; Matschke J; Roth P; Suresh MP; Kamp MA; Rushing EJ; Pietsch T; von Deimling A; Sabel M; Loeffler M; Weller M; Reifenberger G
Eur J Cancer; 2021 Apr; 147():84-94. PubMed ID: 33631540
[TBL] [Abstract][Full Text] [Related]
12. Molecular Diagnostics of Gliomas Using Next Generation Sequencing of a Glioma-Tailored Gene Panel.
Zacher A; Kaulich K; Stepanow S; Wolter M; Köhrer K; Felsberg J; Malzkorn B; Reifenberger G
Brain Pathol; 2017 Mar; 27(2):146-159. PubMed ID: 26919320
[TBL] [Abstract][Full Text] [Related]
13. Correlation between IDH, ATRX, and TERT promoter mutations in glioma.
Ohba S; Kuwahara K; Yamada S; Abe M; Hirose Y
Brain Tumor Pathol; 2020 Apr; 37(2):33-40. PubMed ID: 32227259
[TBL] [Abstract][Full Text] [Related]
14. The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas.
Lee Y; Koh J; Kim SI; Won JK; Park CK; Choi SH; Park SH
Acta Neuropathol Commun; 2017 Aug; 5(1):62. PubMed ID: 28851427
[TBL] [Abstract][Full Text] [Related]
15. A tailored next-generation sequencing panel identified distinct subtypes of wildtype IDH and TERT promoter glioblastomas.
Higa N; Akahane T; Yokoyama S; Yonezawa H; Uchida H; Takajo T; Kirishima M; Hamada T; Matsuo K; Fujio S; Hanada T; Hosoyama H; Yonenaga M; Sakamoto A; Hiraki T; Tanimoto A; Yoshimoto K
Cancer Sci; 2020 Oct; 111(10):3902-3911. PubMed ID: 32748499
[TBL] [Abstract][Full Text] [Related]
16. Validation of multi-gene panel next-generation sequencing for the detection of BRCA mutation in formalin-fixed, paraffin-embedded epithelial ovarian cancer tissues.
Kim ET; Jeong HE; Yoon HJ; Kim KH; Suh DS
Taiwan J Obstet Gynecol; 2023 Jan; 62(1):66-70. PubMed ID: 36720553
[TBL] [Abstract][Full Text] [Related]
17. Spectrum of germline mutations in RB1 in Chinese patients with retinoblastoma: Application of targeted next-generation sequencing.
Zou Y; Li J; Hua P; Liang T; Ji X; Zhao P
Mol Vis; 2021; 27():1-16. PubMed ID: 33456302
[TBL] [Abstract][Full Text] [Related]
18. Significance of TERT and ATRX mutations in glioma.
Liu J; Zhang X; Yan X; Sun M; Fan Y; Huang Y
Oncol Lett; 2019 Jan; 17(1):95-102. PubMed ID: 30655743
[TBL] [Abstract][Full Text] [Related]
19. Direct comparison of the next-generation sequencing and iTERT PCR methods for the diagnosis of TERT hotspot mutations in advanced solid cancers.
Kang SY; Kim DG; Kim H; Cho YA; Ha SY; Kwon GY; Jang KT; Kim KM
BMC Med Genomics; 2022 Feb; 15(1):25. PubMed ID: 35135543
[TBL] [Abstract][Full Text] [Related]
20. Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy.
Wu RC; Ayhan A; Maeda D; Kim KR; Clarke BA; Shaw P; Chui MH; Rosen B; Shih IeM; Wang TL
J Pathol; 2014 Mar; 232(4):473-81. PubMed ID: 24338723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]